The journey from pipeline to portfolio grows more complex, but we are precise in our processes and certain in our science. We’ve grown as you’ve grown, evolving within our changing industry — while always staying true to the scientific expertise and advanced technology that comprise the foundation of our company. Here are a few of our most recent developments.

Timeline

1991
June 19

1991

Thomas E. D’Ambra, Ph.D., co-founds Albany Molecular Research, Inc.

1999
June 19

1999

Albany Molecular Research, Inc. becomes a publicly traded company on the NASDAQ.

2007
June 19

2007

Albany Molecular Research, Inc., changes its name to AMRI to reflect our evolution into a global contract services and R&D organization.

2014
April 19

April 2014

Acquisition of Cedarburg Pharmaceuticals, Inc. The Grafton, Wisc., company develops and manufactures complex APIs including controlled substances and steroids, allowing us to offer a greater breadth of resources, including expanded scale-up capabilities and large-scale manufacturing at lower costs.

July 19

July 2014

Acquisition of Oso BioPharmaceuticals Manufacturing, a premier contract manufacturer of complex injectable drug products and a former portfolio company of Altaris Capital Partners, LLC. The acquisition complements our custom and complex drug product development and manufacturing offerings, making AMRI a single source for addressing sterile fill/finish needs from Phase I development through large-scale commercial supply.

2015
January 19

January 2015

Acquisition of two Aptuit businesses — SSCI, a West Lafayette, Ind., company, and Aptuit’s Glasgow, U.K., facility. These acquisitions strengthen key areas. SSCI provides expert material science knowledge and technology that expand AMRI’s analytical testing capabilities, and the Glasgow operation includes sterile injectable drug product formulation and clinical manufacturing that extend our parenteral offerings, particularly in Europe.

July 19

July 2015

Acquisition of Gadea Pharmaceutical Group, a privately held company in Valladolid, Spain. The acquisition bolsters AMRI’s development and manufacturing services in both branded and generic pharmaceuticals and expands our API portfolio — strengthening our capabilities in steroids and hormones and sterile drug product offerings in ophthalmic and parenteral suspension dosage forms, prefilled syringes and lyophilization.

December 19

December 2015

Acquisition of Whitehouse Laboratories, a Lebanon, N.J.-based provider of testing services including materials and excipients, container qualification and container closure integrity testing, analytical chemistry, drug delivery systems and device qualification programs, packaging, distribution, and stability and storage programs. The acquisition extends AMRI’s state-of-the-art solutions to meet increasingly complex analytical and testing needs.

December 19

December 2015

Launch of integrated drug discovery center in Buffalo, N.Y., in partnership with New York State as a founding member of the Buffalo Medical Innovation and Commercialization Hub. The center provides a single site for biology, high-throughput screening, in vitro pharmacology and medicinal chemistry for increased collaboration and speed in decision making to accelerate innovation.

2016
July 19

July 2016

Acquisition of Prime European Therapeuticals S.p.A., also known as Euticals, a privately held company headquartered in Lodi, Italy. Euticals’ custom synthesis and API manufacturing capabilities broadens AMRI’s custom synthesis offerings in key European markets and positions us as one of the largest independent developers and suppliers of APIs to the pharma industry.